Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1983 2
1985 3
1986 2
1987 1
1988 13
1989 12
1990 17
1991 18
1992 14
1993 14
1994 11
1995 6
1996 11
1997 13
1998 17
1999 19
2000 23
2001 29
2002 31
2003 40
2004 47
2005 65
2006 81
2007 86
2008 123
2009 113
2010 138
2011 159
2012 208
2013 244
2014 294
2015 377
2016 406
2017 431
2018 504
2019 580
2020 695
2021 774
2022 887
2023 845
2024 1000
2025 53

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,557 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Among authors: wen x. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR. Herbst RS, et al. Among authors: wen x. N Engl J Med. 2020 Oct 1;383(14):1328-1339. doi: 10.1056/NEJMoa1917346. N Engl J Med. 2020. PMID: 32997907 Clinical Trial.
Ligand recognition and allosteric regulation of DRD1-Gs signaling complexes.
Xiao P, Yan W, Gou L, Zhong YN, Kong L, Wu C, Wen X, Yuan Y, Cao S, Qu C, Yang X, Yang CC, Xia A, Hu Z, Zhang Q, He YH, Zhang DL, Zhang C, Hou GH, Liu H, Zhu L, Fu P, Yang S, Rosenbaum DM, Sun JP, Du Y, Zhang L, Yu X, Shao Z. Xiao P, et al. Among authors: wen x. Cell. 2021 Feb 18;184(4):943-956.e18. doi: 10.1016/j.cell.2021.01.028. Epub 2021 Feb 10. Cell. 2021. PMID: 33571432 Free PMC article.
The "Self-Sacrifice" of ImmuneCells in Sepsis.
Wen X, Xie B, Yuan S, Zhang J. Wen X, et al. Front Immunol. 2022 Apr 29;13:833479. doi: 10.3389/fimmu.2022.833479. eCollection 2022. Front Immunol. 2022. PMID: 35572571 Free PMC article. Review.
7,557 results